Oestrogen receptor: a stable phenotype in breast cancer.

We previously reported that the anti-tumour effect of OK-432 is considerably enhanced by its intratumoral injection together with fibrinogen. In the present study, we generated killer T cells by culturing tumour-infiltrating lymphocytes from thyroid cancer patients who had received this local immunotherapy. Phenotypic analysis revealed that the T cells were positive for CD3+, CD4+, Leu8-, CD45RO+ and T-cell receptor (TCR)alpha beta+, as well as showing strong surface expression of HLA-DR, CD25, LFA-1 and ICAM-1. The generated CD4+ T cells secreted interferon (IFN)-gamma, tumour necrosis factor (TNF)-alpha, TNF-beta, and interleukin (IL)-6 (but not IL-4), and exhibited a high level of cytolytic activity against several tumour cell lines. The cytolytic activity of these T cells for Daudi cells was inhibited by preincubation with an anti-intercellular adhesion molecule (ICAM)-1 antibody, but not by preincubation with anti-TCR alpha beta, anti-CD2, or anti-LFA-1 antibodies. Pretreatment with anti-ICAM-1 antibody inhibited T-cell cytolytic activity, but not conjugation with target cells. In addition, incubation with immobilised anti-ICAM-1 enhanced the secretion of IFN-gamma by T cells. We conclude that ICAM-1 expressed on the effector cytotoxic CD4+ T lymphocytes delivers regulatory signals that enhance IFN-gamma secretion.

• Publication year

  1996

• Venue

  British Journal of Cancer

• Publication date

  1996-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/bjc.1996.20PMID 8554983PMCID 2074300
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Estrogen receptor immunohistoohemistry in carcinoma in situ of the breast

  2010cited by this paper
• Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer

  2005cited by this paper
• The relationship between estrogen receptors in primary and secondary breast carcinomas and in sequential primary breast carcinomas

  2005cited by this paper
• Measurement of steroid hormone receptors in breast cancer patients on tamoxifen

  2004cited by this paper
• The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth

  2004cited by this paper
• Clinical pharmacology of tamoxifen and N-desmethyltamoxifen in patients with advanced breast cancer

  2004cited by this paper
• Antiestrogen resistance in ER positive breast cancer cells

  2004cited by this paper
• Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression

  2004cited by this paper
• Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.

  1995cited by this paper
• Response to specific anti-oestrogen (ICI182780) in tamoxifen-resistant breast cancer.

  1995cited by this paper
• Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.

  1994cited by this paper
• The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-beta 1 in metastatic human breast cancer: an immunocytochemical study.

  1994cited by this paper
• Cyclical Activity and ‘Ageing’ of the Human Breast: Clues to Assessment of Risk and Strategies for Prevention

  1994cited by this paper
• Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer.

  1994cited by this paper
• Drug Resistance to Antioestrogen Therapy

  1994cited by this paper
• Pure antioestrogens in breast cancer - experimental and clinical observations

  1994cited by this paper
• Cross-linking of ICAM-1 induces co-signaling of an oxidative burst from mononuclear leukocytes.

  1994cited by this paper
• Preparation of a human monoclonal antibody derived from cervical lymph nodes of a patient with anaplastic carcinoma of the thyroid

  1993cited by this paper
• Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism.

  1993cited by this paper
• Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications.

  1993cited by this paper
• Cell-mediated cytotoxicity: contact and secreted factors.

  1993cited by this paper
• A Cancer‐reactive Human Monoclonal Antibody Derived from a Colonic Cancer Patient Treated with Local Immunotherapy

  1993cited by this paper
• Molecular mechanisms of resistance to tamoxifen therapy in breast cancer.

  1993cited by this paper
• Augmentation of antitumor immunity in regional lymph nodes by local immunotherapy

  1993cited by this paper
• Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.

  1993cited by this paper
• Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.

  1993cited by this paper
• Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.

  1993cited by this paper
• Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration.

  1993cited by this paper
• MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.

  1993cited by this paper
• Establishment of cytotoxic CD4+ T cell clones from cancer patients treated by local immunotherapy

  1992cited by this paper
• Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.

  1992cited by this paper
• The cytotoxic process of CD4 Th1 clones.

  1992cited by this paper
• Oestrogen and progesterone receptors in screen‐detected breast carcinoma: an immunohistological study using paraffin sections

  1992cited by this paper
• Stimulation of IFN-γ, TNF-α, and TNF-β secretion in IL-2-activated T cells: Costimulatory roles for LFA-1, LFA-2, CD44, and CD45 molecules

  1992cited by this paper
• Interleukin-1 inhibits human thyroid carcinoma cell growth

  1992cited by this paper
• Heterogeneity of oestrogen receptor expression in normal and malignant breast tissue.

  1992cited by this paper
• Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer.

  1992influential reference
• Role of intercellular adhesion molecule-1 in the inflammatory response.

  1992cited by this paper
• A Human Monoclonal Antibody Derived from Axillary Lymph Nodes of a Breast Cancer Patient Reactive to a Sulfated Glycolipid

  1992cited by this paper
• Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH

  1992cited by this paper
• Receptors for estrogen and progesterone in breast carcinoma in situ.

  1992cited by this paper
• Use of fibrinogen to enhance the antitumor effect of OK‐432. A new approach to immunotherapy for colorectal carcinoma

  1992cited by this paper
• Adhesion molecule‐mediated signals regulate major histocompatibility complex‐unrestricted and CD3/T cell receptor‐triggered cytotoxicity

  1992cited by this paper
• Human atopen-specific types 1 and 2 T helper cell clones.

  1991cited by this paper
• Use of a rapid microwave fixation technique for immunocytochemical demonstration of tumor necrosis factor, interleukin-1α, and interleukin-1β in activated human peripheral mononuclear cells

  1991cited by this paper
• Cellular effects of tamoxifen in primary breast cancer

  1991cited by this paper
• Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.

  1991cited by this paper
• Complementary roles for CD2 and LFA‐1 adhesion pathways during T cell activation

  1991cited by this paper
• Remote T cell co‐stimulation via LFA‐1/ICAM‐1 and CD2/LFA‐3: Demonstration with immobilized ligand/mAb and implication in monocyte‐mediated co‐stimulation

  1991cited by this paper
• Human TH1 and TH2 subsets: doubt no more.

  1991cited by this paper
• Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation.

  1991cited by this paper
• Variant human breast tumor estrogen receptor with constitutive transcriptional activity.

  1991cited by this paper
• Mechanism of tumoricidal activity of OK-432-specific L3T4+ Lyt2- T-cells.

  1990cited by this paper
• Characterization of the estrogen receptor in two antiestrogen-resistant cell lines, LY2 and T47D.

  1990cited by this paper
• Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.

  1990cited by this paper
• Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells.

  1990cited by this paper
• Adhesion receptors of the immune system

  1990cited by this paper
• Expression of two distinct cytolytic mechanisms among murine CD4 subsets.

  1990cited by this paper
• Estrogen receptors in ductal carcinoma in situ of breast.

  1990cited by this paper
• Leukocyte function-associated antigen 1 is an activation molecule for human T cells

  1989cited by this paper
• Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines

  1989cited by this paper
• Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens.

  1989cited by this paper
• Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: Relationship to estrogen receptor and lymphatic invasion

  1989cited by this paper
• CD4+ cytolytic T cell clones restricted to HLA class II, DRβI and DRβIII chains

  1989cited by this paper
• Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.

  1989cited by this paper
• Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study

  1989cited by this paper
• Characterisation of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9a1) and ability of the resistant phenotype.

  1989cited by this paper
• Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy.

  1989cited by this paper
• Biological response modifier as antigen: OK432-specific T-cell clone as an anti-tumor effector cell.

  1989cited by this paper
• Relation between immunocytochemical estimation of oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen.

  1989cited by this paper
• Immunocytochemical localization of estrogen receptor in human breast tissue.

  1988cited by this paper
• The cytochemical detection of oestrogen receptors in fine needle aspirates of breast cancer; correlation with biochemical assay and prediction of response to endocrine therapy.

  1988cited by this paper
• Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration.

  1988cited by this paper
• Steroid receptors, cellular kinetics, and lymph node status as prognostic factors in breast cancer.

  1988cited by this paper
• Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle

  1988cited by this paper
• Steroid receptors and other prognostic factors in primary breast cancer.

  1988cited by this paper
• CD45R gives immunofluorescence and transduces signals on mouse T cells

  1988cited by this paper
• Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behavior over time

  1988cited by this paper
• Purified lymphocyte function-associated antigen-3 (LFA-3) activates human thymocytes via the CD2 pathway.

  1988cited by this paper
• Review: Steroid Receptors, Cellular Kinetics, and Lymph Node Status as Prognostic Factors in Breast Cancer

  1988cited by this paper
• Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy.

  1987cited by this paper
• Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates.

  1987cited by this paper
• Experience with new assays for oestrogen receptors using monoclonal antibodies

  1987cited by this paper
• Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

  1987cited by this paper
• Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer.

  1987cited by this paper
• Prognostic significance of oestrogen and progestogen receptor activities in breast cancer

  1987cited by this paper
• Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases.

  1987cited by this paper
• Monoclonal antibody technique for detection of estrogen receptors in human breast cancer: greater sensitivity and more accurate classification of receptor status than the dextran-coated charcoal method.

  1987cited by this paper
• Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma.

  1986cited by this paper
• Quality control requirements in estrogen receptor determination.

  1986cited by this paper
• Evaluation of an enzyme immunoassay for estrogen receptors in human breast cancers.

  1986cited by this paper
• Abbott monoclonal enzyme immunoassay measurement of estrogen receptors in human breast cancer: a European multicenter study.

  1986cited by this paper
• Determination of estrogen receptor in breast cancer using monoclonal antibody technology: results of a multicenter study in the United States.

  1986cited by this paper
• Immunocytochemical assay for estrogen receptor: relationship to outcome of therapy in patients with advanced breast cancer.

  1986cited by this paper
• Immunohistochemical measurement of estrogen receptors in breast cancer tissue samples.

  1986influential reference
• A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1.

  1986cited by this paper
• Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors.

  1986cited by this paper
• Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy.

  1986cited by this paper
• A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

  1986cited by this paper
• Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer.

  1985cited by this paper

• Study of Drug Targets Associated With Oncogenesis and Cancer Cell Survival and the Therapeutic Activity of Engineered Ashwagandha Extract Having Differential Withanolide Constitutions

  2024cites this paper
• CD4+ Cytotoxic T Lymphocytes in Cancer Immunity and Immunotherapy

  2022cites this paper
• Differential distribution and prognostic value of CD4+ T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes

  2022cites this paper
• Estrogen receptor expression in normal breast epithelium in invasive ductal carcinoma

  2020cites this paper
• Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance

  2020cites this paper
• Insights into how phosphorylation of estrogen receptor at serine 305 modulates tamoxifen activity in breast cancer.

  2019cites this paper
• Solitary Hypothalamus Triple Negative Metastasis from Luminal: A Primary Breast Carcinoma

  2017cites this paper
• Statins, HMGCR and Breast Cancer

  2017cites this paper
• Pre-operative diagnosis and prognostic evaluation of carcinoma breast: A comparative analysis of conventional FNAC and liquid based cytology

  2016cites this paper
• The analysis of estrogen receptor-α positive breast cancer stem-like cells unveils a high expression of the serpin proteinase inhibitor PI-9: Possible regulatory mechanisms.

  2016cites this paper
• Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial

  2015cites this paper
• Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer.

  2015cites this paper
• PARITY, OBESITY AND BREAST CANCER SURVIVAL: DOES INTRINSIC SUBTYPE MODIFY OUTCOMES?

  2015influential citation
• Changing the endocrine dependence of breast cancer: data and hypotheses.

  2014cites this paper
• Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation

  2014cites this paper
• Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer

  2014cites this paper
• Prognostic significance of interactions between ER alpha and ER beta and lymph node status in breast cancer cases.

  2013cites this paper
• Concordant Expression of Estrogen and Progesterone Receptors in Primary and Loco-regional Recurrent Breast Cancer

  2013cites this paper
• DNA in Situ during Progression of Breast Cancer Cells Altered Profiles in Nuclear Matrix Proteins Associated with

  2013cites this paper
• 3URJQRVWLF6LJQL¿FDQFHRI,QWHUDFWLRQV%HWZHHQ(5$OSKDDQG (5%HWDDQG/\PSK1RGH6WDWXVLQ%UHDVW&DQFHU&DVHV

  2013cites this paper
• Significance of biomarker discordance in breast cancer from the pathologist's perspective

  2012cites this paper
• Use of preclinical and early clinical data for dose selection of a selective estrogen receptor modulator toremifene in treatment of breast cancer

  2012cites this paper
• Tamoxifen Resistance in Breast Cancer

  2012cites this paper
• Stability of estrogen receptor status in breast carcinoma

  2011cites this paper
• Between-Patient and Within-Patient (Site-to-Site) Variability in Estrogen Receptor Binding, Measured In Vivo by 18F-Fluoroestradiol PET

  2011cites this paper
• Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.

  2011cites this paper
• ER-Alpha36 Mediates Non-Genomic Estrogen and Anti-Estrogen Signaling in Breast Cancer Cells

  2011cites this paper
• Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells

  2011cites this paper
• Clinical significance of estrogen receptor phosphorylation.

  2011cites this paper
• Aromatase inhibitors: prediction of response and nature of resistance

  2010influential citation
• Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk

  2010cites this paper
• Prognostic and Treatment Predictive Markers Associated with Cyclin D1 Gene Amplification and Epithelial-Mesenchymal Transition in Breast Cancer

  2010cites this paper
• Breast cancer progression is modulated by inherited genetic variance in multiple independent cohorts

  2010cites this paper
• Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

  2010cites this paper
• Combinatorial biomarker expression in breast cancer

  2010cites this paper
• Estradiol-Induced Regression in T47D:A18/PKCα Tumors Requires the Estrogen Receptor and Interaction with the Extracellular Matrix

  2009cites this paper
• SYNTHESIS AND EVALUATION OF PROUTEOLYSIS TAURGETING CHIMERAS (PROTACs): A POTENTIAL CHEMICAL GENETIC APPROACH TO BREAST CANCER THERAPY

  2009cites this paper
• Mitogen-activated protein kinase family members and endocrine response and survival in breast cancer

  2008cites this paper
• Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer.

  2008cites this paper
• The effect of chemotherapy on status of estrogen receptors in primary tumors and lymph node metastases of human ductal breast cancer.

  2007cites this paper
• Femara® and the future: tailoring treatment and combination therapies with Femara

  2007cites this paper
• Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells.

  2007cites this paper
• Growth factor signalling in endocrine and anti-growth factor resistant breast cancer

  2007cites this paper
• The Role of RB in the Therapeutic Response of Breast Cancer

  2007cites this paper
• RB in Breast Cancer: The Crossroads of Tumorigenesis and Treatment

  2007cites this paper
• Genetic screening reveals an essential role of p27kip1 in restriction of breast cancer progression.

  2007influential citation
• The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.

  2007influential citation
• Biomolecular markers of breast cancer.

  2006cites this paper
• Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth

  2006cites this paper
• Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.

  2006cites this paper
• Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression.

  2006cites this paper
• Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.

  2006cites this paper
• Estrogen receptors as therapeutic targets in breast cancer.

  2006cites this paper
• Phosphorylation of ERa at serine 118 in primary breast cancer and in tamoxifen- resistant tumours is indicative of a complex role for ERa phosphorylation in breast cancer progression

  2006cites this paper
• Metastatic breast cancer: an updating.

  2006cites this paper
• Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy.

  2006cites this paper
• Fever, Pyrogens and Cancer

  2006cites this paper
• Breast cancer heterogeneity: a mixture of at least two main types?

  2006cites this paper
• Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression

  2006cites this paper
• Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance

  2006cites this paper
• Fulvestrant (ICI 182,780)-dependent Interacting Proteins Mediate Immobilization and Degradation of Estrogen Receptor-α*

  2006cites this paper
• Observations on the presence of E domain variants of estrogen receptor‐α in the breast tumors

  2006cites this paper
• Role of oestrogen receptor phosphorylation in the growth of endocrine-responsive and anti-oestrogen-resistant breast cancer cell lines

  2005cites this paper
• Epidemiology and Prevention of Breast Cancer

  2005cites this paper
• Serum HER‐2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy

  2005cites this paper
• Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene.

  2005cites this paper
• In vitro and in vivo Effects of Combination of Trastuzumab (Herceptin) and Tamoxifen in Breast Cancer

  2005cites this paper
• Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM.

  2005cites this paper
• Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor β but not the estrogen receptor α gene

  2005cites this paper
• Immunoreactive estrogen receptor in breast tumor and adjacent tissue: Association with clinicopathological characteristics in Indian population

  2005cites this paper
• Gene expression profiles in breast tumors regarding the presence or absence of estrogen and progesterone receptors

  2004cites this paper
• Polyunsaturated Fatty Acids and the Epidermal Growth Factor Receptor/ Mitogen- Activated Protein Kinase Signal Transduction Cascade in Mammary Cancer

  2004cites this paper
• Risk factors for breast cancer according to estrogen and progesterone receptor status.

  2004cites this paper
• Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo.

  2004cites this paper
• Change in Expression of ER, bcl-2 and MIB1 on Primary Tamoxifen and Relation to Response in ER Positive Breast Cancer

  2004cites this paper
• Phospho-Serine-118 Estrogen Receptor-α Detection in Human Breast Tumors in Vivo

  2004cites this paper
• Leitlinienorientierte Therapie des Mammakarzinoms: Kontroversen in der individuellen Betreuung

  2004cites this paper
• Intermittent Hypoxia Induces Proteasome-Dependent Down-Regulation of Estrogen Receptor α in Human Breast Carcinoma

  2004cites this paper
• Biological rationale for endocrine therapy in breast cancer.

  2004cites this paper
• Mifepristone Induces Growth Arrest, Caspase Activation, and Apoptosis of Estrogen Receptor-Expressing, Antiestrogen-Resistant Breast Cancer Cells

  2004cites this paper
• Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway

  2004cites this paper
• Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies.

  2003cites this paper
• Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.

  2003cites this paper
• Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.

  2003cites this paper
• Oestrogen Receptor-Mediated Modulation of the EGFR/MAPK Pathway in Tamoxifen-Resistant MCF-7 Cells

  2003cites this paper
• Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity.

  2003cites this paper
• Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy.

  2003cites this paper
• Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest

  2002cites this paper
• Rates for Breast Cancer Characteristics by Estrogen and Progesterone Receptor Status in the Major Racial/Ethnic Groups

  2002cites this paper
• Characterization of stably transfected fusion protein GFP‐estrogen receptor‐α in MCF‐7 human breast cancer cells

  2002cites this paper
• Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database

  2002cites this paper
• Guidelines on endocrine therapy of breast cancer EUSOMA.

  2002cites this paper
• Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.

  2002cites this paper
• Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera

  2002cites this paper
• Estrogen receptor-alpha mRNA in primary breast cancer: relationship to estrogen and progesterone receptor proteins and other prognostic factors.

  2002cites this paper
• Non‐competitive steroid inhibition of oestrogen receptor functions

  2002cites this paper
• Tumour location and prognostic characteristics as determinants of survival of women with invasive breast cancer: South Australian hospital-based cancer registries, 1987-1998.

  2002cites this paper
• The greater impact of menopause on ER– than ER+ breast cancer incidence: a possible explanation (United States)

  2002cites this paper
• Steroid receptors in human breast tumorigenesis and breast cancer progression.

  2002cites this paper
• Delay in the clinical diagnosis of breast cancer: estimating its effect on prognosis, with particular reference to medical litigation.

  2002cites this paper